Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith L Knutson

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Nature Medicine|April 22, 2003
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunityTyler J Curiel, Shuang Wei, Haidong Dong, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|December 20, 2021
Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer PatientsSaranya Chumsri, Pooja P Advani, Tanmayi S Pai, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.
Cancer Research|April 15, 2014
Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancerChen Wang, Mine S Cicek, Bridget Charbonneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.
NPJ Breast Cancer|February 13, 2020
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patientsNadine Norton, Bahaaeldin Youssef, David W Hillman, et al.
Breast Cancer Research : BCR|June 10, 2024
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancerRoberto A Leon-Ferre, Kaitlyn R Whitaker, Vera J Suman, et al.
Journal for Immunotherapy of Cancer|June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancerYi Liu, Jodi M Carter, Yaohua Ma, et al.
NPJ Breast Cancer|May 24, 2022
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trialsSaranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Nature Communications|October 15, 2020
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patientsMatthew S Block, Allan B Dietz, Michael P Gustafson, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Nature Medicine|April 22, 2003
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunityTyler J Curiel, Shuang Wei, Haidong Dong, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|December 20, 2021
Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer PatientsSaranya Chumsri, Pooja P Advani, Tanmayi S Pai, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.
Cancer Research|April 15, 2014
Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancerChen Wang, Mine S Cicek, Bridget Charbonneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.
NPJ Breast Cancer|February 13, 2020
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patientsNadine Norton, Bahaaeldin Youssef, David W Hillman, et al.
Breast Cancer Research : BCR|June 10, 2024
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancerRoberto A Leon-Ferre, Kaitlyn R Whitaker, Vera J Suman, et al.
Journal for Immunotherapy of Cancer|June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancerYi Liu, Jodi M Carter, Yaohua Ma, et al.
NPJ Breast Cancer|May 24, 2022
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trialsSaranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Nature Communications|October 15, 2020
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patientsMatthew S Block, Allan B Dietz, Michael P Gustafson, et al.
Pageof 15